A Phase I Study of Multiple Doses of Neural Stem Cell-Based Oncolytic Virotherapy (NSC-CRAd-S-pk7) Administered Intracerebrally to Patients With Recurrent High-Grade Gliomas

Trial ID: NCT05139056

Interventional - Phase 1 - Recruiting

This phase I trial studies the safety of giving multiple intracerebral doses of NSC-CRAd-S-pk7 to treat patients with glioblastoma at first recurrence. NSC-CRAd-S-pk7 consists of neural stem cells that can target glioblastoma cells and carry a virus, which can kill cancer cells. Giving multiple doses of NSC-CRAd-S-pk7 may kill more tumor cells.

Conditions

• Currently Only Enrolling Glioblastoma Patients at First Recurrence

Interventions

• Neural Stem Cells-expressing CRAd-S-pk7
• Resection

Eligibility

Inclusion criteria

• Patient must be age \>= 18 years
• Patient has a Karnofsky performance status of \>= 70%
• Patient has a life expectancy of \>= 3 months
• When determining the maximum tolerated number of treatment cycles (MTC): patient has a histologically confirmed diagnosis of a grade 3 or 4 glioma (eg., glioblastoma, grade 4 astrocytoma, grade 3 astrocytoma, grade 3 oligodendroglioma). (This part of the study has been completed).
• When enrolling to Treatment Schedules 4 and 4a: patient has glioblastoma at first recurrence.
• Imaging studies show evidence of recurrent, supratentorial tumor(s).
• Patient's high-grade glioma has recurred or progressed after prior treatment with brain radiation and temozolomide
• The patient must be in need of surgery for tumor resection
• Based on the neurosurgeon's judgment, there is no anticipated physical connection between the post-resection tumor cavity and the cerebral ventricles
• Absolute neutrophil count (ANC) of \>= 1000 cells/mm\^3
• Platelet count \>= 100,000 cells/mm\^3
• Total bilirubin =\< 2.0 mg/dl
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) =\< 4 times the institutional upper limit of normal
• Serum creatinine =\< the institutional upper limit of normal
• At least 2 weeks from taking the last dose of a targeted agent
• At least 4 weeks from the last dose of bevacizumab For temozolomide, an interval of 23 days is required from the last dose administered if the patient was recently treated with adjuvant temozolomide, consisting of temozolomide daily for 5 days, repeated every 28 days.
• At least 2 weeks from taking the last dose of a targeted agent.
• At least 4 weeks from the last dose of bevacizumab.
• All significant toxicities from previous anticancer therapy must have stabilized to a new baseline or resolved.
• All participants must have the ability to understand and the willingness to sign a written informed consent.
• The effects of this treatment on a developing fetus are unknown. Therefore, female patients of childbearing potential and sexually-active male patients or who are able to impregnate their partner, must agree to use an effective method of contraception while participating in this study. Patients of childbearing potential must have a negative pregnancy test =\< 2 week prior to registration.

Exclusion criteria

• Patient has multi-focal disease.
• Patient is receiving radiation, chemotherapy, or another investigational agent.
• Patient has had prior therapy with neural stem cells.
• Patient has not recovered from any toxicity (\> grade 1) of prior therapies, except alopecia.
• Patient is unable to undergo a brain MRI.
• Patient has chronic or active viral infections of the central nervous system (CNS).
• Patient has a coagulopathy or bleeding disorder.
• Patient has an uncontrolled illness including ongoing or active infection.
• Patient has another active malignancy.
• Patient is pregnant or breastfeeding.
• A patient has a serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the safety monitoring requirements and completion of treatment according to this protocol.

Sponsor

City of Hope Medical Center, National Cancer Institute (NCI)

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows